Beiersdorf (BEI) Q4 2025 earnings summary

Executive summary

• Group sales reached €9.9 billion in 2025, up 2.4% organically, with EBIT margin excluding special factors rising to 14.0%.

• Maintained global leadership in skincare for the third consecutive year, driven by science-based innovation, global expansion, and a culture of care.

• Derma business delivered double-digit growth for the fifth year, while NIVEA saw modest 0.9% growth amid strategic recalibration and La Prairie declined 4.5% organically.

• tesa achieved €1.7 billion in sales, up 1.8% organically, despite market headwinds.

• Beiersdorf outperformed key competitors and remains the fastest growing skin care company.

Financial highlights

• Group net sales grew to €9.852 billion in 2025; organic sales growth was 2.4%.

• EBIT (excluding special factors) increased to €1.4 billion, with a margin of 14.0%.

• Earnings per share rose to €4.25, up 4.9% from 2024.

• Consumer business net sales reached €8.2 billion, with organic growth of 2.5%.

• Tesa business delivered 1.8% organic growth, with net sales of €1.7 billion.

Outlook and guidance

• 2026 guidance: flat to slightly positive organic sales growth expected across all segments; Q1 2026 anticipated to be low single-digit negative due to US and China retail disruptions.

• EBIT margin (excluding special factors) expected to be slightly below 2025 due to raw material costs, FX, and limited fixed cost leverage.

• Strategic focus on NIVEA rebalancing, innovation, and expansion into new markets; continued commitment to profitable growth and shareholder returns.